The short version
5 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Neomycin and Polymyxin B Sulfates and Dexamethasone
Neomycin Sulfate, Polymyxin B Sulfate, and Dexamethasone · NEOMYCIN SULFATE 3.5 mg/g; POLYMYXIN B SULFATE 10000 [USP'U]/g; DEXAMETHASONE 1 mg/g · Ointment · Ophthalmic · Preferred Pharmaceuticals Inc.
NDC 68788-8748-03 · 1 TUBE in 1 CARTON / 3.5 g in 1 TUBE · ANDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 24208-0795-35) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$3.31per unit
middle half $2.12–$4.36 · 5,496 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $3.31
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
100%of plans cover it
tier 2 · prior auth 0% · step therapy 0% · qty limit 0%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 2 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for neomycin sulfate, polymyxin b sulfate and dexamethasone (other) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Where it's made
- Preferred Pharmaceuticals Inc.United Statesrelabel
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Regulatory
- Application
- ANDA064063
- TE code
- AT
- Approval date
- Jul 25, 1994
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Neomycin Sulfate, Polymyxin B Sulfate, and Dexamethasone (Ointment)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| A-S Medication Solutions | NEOMYCIN SULFATE 3.5 mg/g; POLYMYXIN B SULFATE 10000 [USP'U]/g; DEXAMETHASONE 1 mg/g | Aug 26, 2026 | Sep 2, 2026 |
| Bausch & Lomb Incorporated | NEOMYCIN SULFATE 3.5 mg/g; POLYMYXIN B SULFATE 10000 [USP'U]/g; DEXAMETHASONE 1 mg/g | Aug 26, 2026 | Sep 2, 2026 |
| NuCare Pharmaceuticals,Inc. | NEOMYCIN SULFATE 3.5 mg/g; POLYMYXIN B SULFATE 10000 [USP'U]/g; DEXAMETHASONE 1 mg/g | Aug 26, 2026 | Sep 2, 2026 |
| Preferred Pharmaceuticals Inc. | NEOMYCIN SULFATE 3.5 mg/g; POLYMYXIN B SULFATE 10000 [USP'U]/g; DEXAMETHASONE 1 mg/g | Aug 26, 2026 | Sep 2, 2026 |
| Proficient Rx LP | NEOMYCIN SULFATE 3.5 mg/g; POLYMYXIN B SULFATE 10000 [USP'U]/g; DEXAMETHASONE 1 mg/g | Aug 26, 2026 | Sep 2, 2026 |
| A-S Medication Solutions | NEOMYCIN SULFATE 1 mg/g; POLYMYXIN B SULFATE 3.5 mg/g; DEXAMETHASONE 10000 [USP'U]/g | Jul 22, 2026 | Aug 19, 2026 |
| Bausch & Lomb Incorporated | NEOMYCIN SULFATE 1 mg/g; POLYMYXIN B SULFATE 3.5 mg/g; DEXAMETHASONE 10000 [USP'U]/g | Jul 22, 2026 | Aug 19, 2026 |
| NuCare Pharmaceuticals,Inc. | NEOMYCIN SULFATE 1 mg/g; POLYMYXIN B SULFATE 3.5 mg/g; DEXAMETHASONE 10000 [USP'U]/g | Jul 22, 2026 | Aug 19, 2026 |
| Preferred Pharmaceuticals Inc. | NEOMYCIN SULFATE 1 mg/g; POLYMYXIN B SULFATE 3.5 mg/g; DEXAMETHASONE 10000 [USP'U]/g | Jul 22, 2026 | Aug 19, 2026 |
| Proficient Rx LP | NEOMYCIN SULFATE 1 mg/g; POLYMYXIN B SULFATE 3.5 mg/g; DEXAMETHASONE 10000 [USP'U]/g | Jul 22, 2026 | Aug 19, 2026 |
| A-S Medication Solutions | DEXAMETHASONE 1 mg/g; NEOMYCIN SULFATE 3.5 mg/g; POLYMYXIN B SULFATE 10000 [USP'U]/g | Jul 15, 2026 | Jul 15, 2026 |
| Bausch & Lomb Incorporated | DEXAMETHASONE 1 mg/g; NEOMYCIN SULFATE 3.5 mg/g; POLYMYXIN B SULFATE 10000 [USP'U]/g | Jul 15, 2026 | Jul 15, 2026 |
| NuCare Pharmaceuticals,Inc. | DEXAMETHASONE 1 mg/g; NEOMYCIN SULFATE 3.5 mg/g; POLYMYXIN B SULFATE 10000 [USP'U]/g | Jul 15, 2026 | Jul 15, 2026 |
| Preferred Pharmaceuticals Inc. | DEXAMETHASONE 1 mg/g; NEOMYCIN SULFATE 3.5 mg/g; POLYMYXIN B SULFATE 10000 [USP'U]/g | Jul 15, 2026 | Jul 15, 2026 |
| Proficient Rx LP | DEXAMETHASONE 1 mg/g; NEOMYCIN SULFATE 3.5 mg/g; POLYMYXIN B SULFATE 10000 [USP'U]/g | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Neomycin and Polymyxin B Sulfates and Dexamethasone — NDC 68788-8748-03," retrieved September 3, 2026, https://drugdashboards.com/drug/68788874803.
Free to cite with attribution — see how the data is put together.